Regeneron Pharmaceuticals Inc. closed $494.52 short of its 52-week high ($1,211.20), which the company achieved on August ...
Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV ...
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $1086.64, a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback